GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00576758. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate the efficacy of weekly intravenous obinutuzumab \[GA101 (RO5072759)\] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma. Patients will be randomized to receive either GA101 or rituximab, given as four weekly infusions. At the conclusion of the initial trial patients may be eligible to continue therapy up to 24 months. The anticipated time on study treatment is 3- 24 months, and the target sample size is 100-500 individuals.
Study identification
- NCT ID
- NCT00576758
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 175 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- Aug 31, 2011
- Completion
- Feb 28, 2013
- Last update posted
- Aug 18, 2014
2008 – 2013
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90024 | — |
| Not listed | Denver | Colorado | 80220 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Augusta | Georgia | 30912 | — |
| Not listed | Cumberland | Maryland | 21502 | — |
| Not listed | Hackensack | New Jersey | 07601 | — |
| Not listed | New York | New York | 10065 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Concord | North Carolina | 28025 | — |
| Not listed | Columbus | Ohio | 43219 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
Recently updated Non-Hodgkin's Lymphoma trials
Other public records listing Non-Hodgkin's Lymphoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT03844048: An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Active, not recruiting
- NCT05618028: Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets Active, not recruiting
- NCT03075696: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma Active, not recruiting
- NCT04002947: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma Recruiting
- NCT00131014: Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies Recruiting
- NCT01890486: The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00576758, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2014 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00576758 live on ClinicalTrials.gov.